Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Adult Rheumatoid Arthritis (RA) participants previously receiving immediate release prednisone were enrolled in the trial if they and their physicians both consented. Once entered, participant baseline data were captured and they were switched to delayed-release prednisone and followed for approximately 12 weeks.
Study with completed results acquired from Horizon in 2024.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 and in general good health (Investigator discretion) with a recent stable medical history other than related to RA disease activity
RA diagnosis is ≥ 6 months according to ACR and/or EULAR classification criteria for diagnosis of active RA
Morning stiffness duration of at least 45 minutes at study entry
RA disease activity as defined by DAS28 of ≥ 3.2 at study entry
Currently receiving conventional immediate-release prednisone ≥ 2.5 milligram (mg) every morning and previously agreed to switch to RAYOS
Willing and able to sign an Informed Consent Form (ICF)
You may not be if
Patient is unwilling to participate in the non-interventional study
